Meeting
2020 ASCO Virtual Scientific Program
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
Authors
Hope S. Rugo
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Hope S. Rugo , Louis W. C. Chow , Javier Cortes , Peter A. Fasching , Pei Hsu , Chiun-Sheng Huang , Sung-Bae Kim , Yen-Shen Lu , Michelle E. Melisko , Rita Nanda , Priyanka Sharma , Richard B. Schwab , Binghe Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NTC03562637
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS599)
DOI
10.1200/JCO.2020.38.15_suppl.TPS599
Abstract #
TPS599
Poster Bd #
91
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419).
First Author: Karl D. Lewis
Poster
2013 ASCO Annual Meeting
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.
First Author: Paul E. Goss
Poster
2022 ASCO Annual Meeting
A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.
First Author: Hope S. Rugo
Poster
2019 ASCO Annual Meeting
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.
First Author: Fatima Cardoso